Stockscreener 앱 받기
41.51
2.42%
0.98
시간 외 거래:
41.71
0.20
+0.48%
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 5.4% in December - MarketBeat
Gene Editing Market Overview and Leading Players: Horizon - openPR
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia - Benzinga
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? - MSN
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential - Insider Monkey
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com India
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
7,536 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Mirador Capital Partners LP - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Vertex's Pain Drug: Big Pharma's Next Major Success? - Benzinga
My 10 Top Stocks to Buy to Start the New Year Off Right - The Motley Fool
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year LowTime to Sell? - MarketBeat
Genome Engineering Market Is Booming Worldwide 2024-2031 | Thermo Fisher Scientific Inc., CRISPR Therapeutics - EIN News
CRISPR Therapeutics' (CRSP) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
How to Take Advantage of moves in (CRSP) - Stock Traders Daily
CRISPR Therapeutics outlines 2025 strategic goals By Investing.com - Investing.com Canada
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month LowWhat's Next? - MarketBeat
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players - Yahoo Finance UK
CRISPR Therapeutics stock hits 52-week low at $38.2 - Investing.com India
CRISPR Therapeutics stock hits 52-week low at $38.2 By Investing.com - Investing.com Nigeria
CRISPR Therapeutics outlines 2025 strategic goals - Investing.com India
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones - GlobeNewswire
CRISPR Therapeutics (CRSP) Highlights Strategic Priorities and Anticipated 2025 Milestones - StreetInsider.com
CRISPR Therapeutics Reveals 2025 Pipeline Plans: CASGEVY Success Drives $1.9B Cash Position - StockTitan
Catherine Wood's Recent Transaction with CRISPR Therapeutics AG - GuruFocus.com
Brookline Capital Management Estimates CRSP FY2024 Earnings - MarketBeat
Equities Analysts Issue Forecasts for CRSP FY2029 Earnings - MarketBeat
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Interesting CRSP Put And Call Options For February 28th - Nasdaq
CRISPR Therapeutics to add Briggs Morrison to Board By Investing.com - Investing.com South Africa
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - MSN
Bank of America Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $85.00 - MarketBeat
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025 - MarketBeat
CRISPR Therapeutics to add Briggs Morrison to Board - Investing.com
Intellia Thera CS (NTLA-Q) QuotePress Release - The Globe and Mail
CRISPR Therapeutics Proposes New Appointment to the Board of Directors - GlobeNewswire
CRISPR Therapeutics Strengthens Board with Former AstraZeneca Clinical Development Leader - StockTitan
Check Out What Whales Are Doing With CRSP - Benzinga
Capital Market Strategies LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
How To Trade (CRSP) - Stock Traders Daily
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - MSN
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up - Simply Wall St
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week LowWhat's Next? - MarketBeat
CRISPR Therapeutics stock hits 52-week low at $39.31 By Investing.com - Investing.com Nigeria
CRISPR Therapeutics stock hits 52-week low at $39.31 - Investing.com
4.81%
자본화:
|
볼륨(24시간):